Rain Oncology Inc (RAIN)

Overview News Price History Option Chain Discussions Forecast

Rain Oncology Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.23 pivot point. If it approaches the $1.13 support level, significant changes may occur.

Rain Oncology Inc Stock (RAIN) Financials Data

Rain Oncology Inc (RAIN) Net Income 2023

RAIN net income (TTM) was -$72.26 million for the quarter ending September 30, 2023, a -1.73% decrease year-over-year.

Rain Oncology Inc (RAIN) Cash Flow 2023

RAIN recorded a free cash flow (TTM) of -$68.44 million for the quarter ending September 30, 2023, a -14.71% decrease year-over-year.

Rain Oncology Inc (RAIN) Earnings per Share 2023

RAIN earnings per share (TTM) was -$2.06 for the quarter ending September 30, 2023, a +23.13% growth year-over-year.

Rain Oncology Inc Stock (RAIN) Latest News

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

GlobeNewswire Inc.

3 Top Penny Stocks to Buy According To Insiders In October

PennyStocks

Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying

Benzinga

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

GlobeNewswire Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Initiated	SVB Securities: Outperform	Mar-21-23
Resumed	ROTH Capital: Buy	Jan-31-23
Initiated	Mizuho: Buy	Jan-23-23
Initiated	H.C. Wainwright: Buy	Sep-12-22
Initiated	Oppenheimer: Outperform	Apr-01-22
Resumed	Goldman: Neutral	Sep-14-21
Initiated	Piper Sandler: Overweight	Jul-20-21
Initiated	Citigroup: Buy	May-18-21
Initiated	Goldman: Buy	May-18-21
Initiated	Guggenheim: Buy	May-18-21
Initiated	Piper Sandler: Overweight	May-18-21